A 34-year-old man with newly diagnosed HIV (CD4 32 cells/µL, VL 480,000 copies/mL) presents with two weeks of severe odynophagia, retrosternal pain, and weight loss. He failed a 5-day trial of fluconazole. Upper endoscopy reveals multiple large linear deep ulcers in the distal esophagus with a clean base and normal surrounding mucosa. Biopsies from the ulcer base show large endothelial and stromal cells with owl-eye intranuclear inclusions and granular cytoplasmic inclusions; immunohistochemistry confirms CMV. Which of the following management approaches is most appropriate for the condition shown at **A** in the diagram?

Question

Accepted Answer

A. IV ganciclovir induction (5 mg/kg every 12 hours for 14–21 days) with biopsy-confirmed CMV inclusions, followed by maintenance valganciclovir and ART initiation within 2 weeks. ## Why IV ganciclovir induction with ART is right

The clinical presentation—large linear deep ulcers in the distal esophagus with owl-eye intranuclear inclusions and granular cytoplasmic inclusions at the ulcer base confirmed by immunohistochemistry—is pathognomonic for CMV esophagitis. According to IDSA OI Guidelines 2024 and Wilcox Gastroenterology 2018, the standard of care is IV ganciclovir induction at 5 mg/kg every 12 hours for 14–21 days, followed by maintenance valganciclovir 900 mg daily until CD4 > 100 cells/µL is sustained on ART for 3–6 months. Critically, ART must be initiated within 2 weeks once tolerated to reduce mortality and allow immune reconstitution. This approach directly addresses the underlying CMV infection and restores immune function.

## Why each distractor is wrong

- **Empirical fluconazole alone**: The patient has already failed a 5-day trial of fluconazole, confirming this is not candidiasis. Fluconazole targets Candida albicans (the most common esophageal infection in HIV), which presents with white plaques and is fluconazole-responsive. Continuing fluconazole delays diagnosis and appropriate CMV therapy, risking severe morbidity and mortality.

- **Acyclovir monotherapy**: Acyclovir is the first-line agent for HSV esophagitis, which classically presents with multiple small shallow ulcers in the proximal-to-mid esophagus with multinucleated giant cells and Cowdry-A intranuclear inclusions at the ulcer edge. CMV esophagitis requires ganciclovir or valganciclovir; acyclovir has poor bioavailability against CMV and is inadequate for this diagnosis.

- **Surgical esophagectomy**: Surgery is not indicated for CMV esophagitis and is reserved only for perforation, uncontrolled bleeding, or stricture refractory to medical management. Esophagectomy carries high morbidity and mortality in an immunocompromised patient with CD4 32 cells/µL and delays life-saving ART initiation. Medical therapy is the standard first-line approach.

**High-Yield:** CMV esophagitis = large linear distal ulcers with owl-eye inclusions at the ulcer base; treat with IV ganciclovir induction + early ART (within 2 weeks), not fluconazole or acyclovir.

[cite: IDSA OI Guidelines in HIV 2024; Wilcox Gastroenterology 2018; Bonacini AIDS 1991]

Answer

B. Surgical esophagectomy with reconstruction and delayed ART initiation to allow wound healing

Answer

C. Empirical fluconazole 400 mg daily for 14–21 days with repeat endoscopy if no response

Answer

D. Acyclovir 800 mg five times daily for 10–14 days with close monitoring of renal function

Explanation

Why IV ganciclovir induction with ART is right

Why each distractor is wrong

Practice similar questions